Brain insulin dysregulation: Implication for neurological and neuropsychiatric disorders

Molecular Neurobiology

Volumn 47, Issue 3, 2013, Pages 1046-1065

  Ghasemi, Rasoul ^a   Dargahi, Leila ^b   Haeri, Ali ^b   Moosavi, Maryam ^a   Mohamed, Zahurin ^c   Ahmadiani, Abolhassan ^b,c  

^a SHIRAZ UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c UNIVERSITY OF MALAYA   (Malaysia)

Author keywords

Alzheimer's disease; Depression; Diabetes mellitus; Huntington's disease; Insulin; Parkinson's disease; Schizophrenia

Indexed keywords

AMYLOID BETA PROTEIN; CHOLESTEROL; INSULIN; SEROTONIN; TAU PROTEIN;

ACYLATION; ALZHEIMER DISEASE; AMYLOID PLAQUE; ANIMAL; ARTICLE; BRAIN; BRAIN LEVEL; COMPLICATION; DEPRESSION; DIABETES MELLITUS; DISEASE SEVERITY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; ENERGY METABOLISM; FOOD INTAKE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; HUMAN; HUNTINGTON CHOREA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BRAIN LEVEL; INSULIN RESISTANCE; MENTAL DISEASE; METABOLISM; NERVE DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROLOGIC DISEASE; NEUROSIS; NEUROTRANSMISSION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PATHOLOGY; PATHOPHYSIOLOGY; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; PSYCHOSIS; REVIEW; SCHIZOPHRENIA; SIGNAL TRANSDUCTION;

ANIMALS; BRAIN; COMPLICATIONS; HUMANS; INSULIN; METABOLISM; NERVOUS SYSTEM DISEASES; NEUROTIC DISORDERS; PATHOLOGY; PHYSIOPATHOLOGY;

EID: 84892780571     PISSN: 08937648     EISSN: 15591182     Source Type: Journal    
DOI: 10.1007/s12035-013-8404-z     Document Type: Article

References (273)

1. Chowers I, Lavy S, Halpern L. (1961) Effect of insulin administered intracisternally in dogs on the glucose level of the blood and the cerebrospinal fluid. Exp Neurol 3(2):197-205
2. Chowers I, Lavy S, Halpern L. (1966) Effect of insulin administered intracisternally on the glucose level of the blood and the cerebro-spinal fluid in vagotomized dogs. Exp Neurol 14(3):383-389
3. Havrankova J, Schmechel D, Roth J., Brownstein M. (1978) Identification of insulin in rat brain. Proc Natl Acad Sci U S A 75(11):5737-5741
4. Havrankova J, Roth J, Brownstein M.J. (1979) Concentrations of insulin and insulin receptors in the brain are independent of peripheral insulin levels. Studies of obese and streptozotocin-treated rodents. J Clin Invest 64(2):636-642. doi:10.1172/JCI109504
5. Margolis RU, Altszuler N. (1967) Insulin in the cerebrospinal fluid. Nature 215:1375-1376
6. Banks WA, Jaspan JB, Huang W, Kastin A.J. (1997) Transport of insulin across the blood-brain barrier: saturability at euglycemic doses of insulin. Peptides 18(9):1423-1429
7. Banks WA, Kastin A.J. (1998) Differential permeability of the blood-brain barrier to two pancreatic peptides: insulin and amy-lin. Peptides 19(5):883-889
8. Baura G, Foster D, Kaiyala K., Porte D, Kahn S, Schwartz M. (1996) Insulin transport from plasma into the central nervous system is inhibited by dexamethasone in dogs. Diabetes 45(1):86
9. Strubbe J, Porte D Jr, Woods S. (1988) Insulin responses and glucose levels in plasma and cerebrospinal fluid during fasting and refeeding in the rat. Physiol Behav 44(2):205-208
10. Florant G, Richardson R, Mahan S., Singer L, Woods S. (1991) Seasonal changes in CSF insulin levels in marmots: insulin may not be a satiety signal for fasting in winter. Am J Physiol Regul Integr Comp Physiol 260(4):R712
11. Kaiyala KJ, Prigeon RL, Kahn S.E., Woods SC, Schwartz M.W. (2000) Obesity induced by a high-fat diet is associated with reduced brain insulin transport in dogs. Diabetes 49(9):1525
12. Dorn A, Bernstein HG, Rinne A, Ziegler M., Hahn HJ, Ansorge S. (1983) Insulin and glucagonlike peptides in the brain. Anat Rec 207(1):69-77
13. Birch NP, Christie DL, Renwick AGC (1984) Proinsulin-like material in mouse foetal brain cell cultures. FEBS Lett 168 (2):299-302
14. Frölich L., Blum-Degen D, Bernstein H.G., Engelsberger S., Humrich J, Laufer S, Muschner D., Thalheimer A, Türk A, Hoyer S (1998) Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm 105(4):423-438
15. Devaskar SU, Singh BS, Carnaghi L.R., Rajakumar PA, Giddings S.J. (1993) Insulin II gene expression in rat central nervous system. Regul Pept 48 (1-2):55-63
16. Young WS III (1986) Periventricular hypothalamic cells in the rat brain contain insulin mRNA. Neuropeptides 8(2):93-97
17. Schechter R, Whitmire J, Wheet G.S., Beju D., Jackson KW, Harlow R, Gavin JR III (1994) Immunohistochemical and in situ hybridization study of an insulin-like substance in fetal neuron cell cultures. Brain Res 636(1):9-27
18. Havrankova J, Roth J, Brownstein M. (1978) Insulin receptors are widely distributed in the central nervous system of the rat. Nature 272(5656):827-829
19. Hill J, Lesniak M, Pert C., Roth J. (1986) Autoradiographic localization of insulin receptors in rat brain: prominence in olfactory and limbic areas. Neuroscience 17(4):1127-1138
20. Schulingkamp R, Pagano T, Hung D., Raffa R. (2000) Insulin receptors and insulin action in the brain: review and clinical implications. Neurosci Biobehav Rev 24(8):855-872
21. LeRoith D, Lowe WL Jr, Shemer J, Raizada MK, Ota A. (1988) Development of brain insulin receptors. Int J Biochem 20 (3):225-230
22. Zahniser NR, Goens MB, Hanaway P.J., Vinych J.V. (1984) Characterization and regulation of insulin receptors in rat brain. J Neurochem 42(5):1354-1362
23. Heidenreich KA, Zahniser NR, Berhanu P, Brandenburg D., Olefsky J.M. (1983) Structural differences between insulin receptors in the brain and peripheral target tissues. J Biol Chem 258(14):8527
24. Yip CC, Moule ML, Yeung CWT (1980) Characterizationofinsulin receptor subunits in brain and other tissues by photoaffinity labeling. Biochem Biophys Res Commun 96(4):1671-1678
25. Shen L, Wang DQH, Tso P, Jandacek R.J., Woods SC, Liu M (2011) Apolipoprotein E reduces food intake via PI3K/Akt signaling pathway in the hypothalamus. Physiol Behav
26. Gerozissis K (2008) Brain insulin, energy and glucose homeosta-sis; genes, environment and metabolic pathologies. Eur J Pharmacol 585(1):38-49
27. Stockhorst U, de Fries D, Steingrueber HJ, Scherbaum W.A. (2004) Insulin and the CNS: effects on food intake, memory, and endocrine parameters and the role of intranasal insulin administration in humans. Physiol Behav 83(1):47-54
28. Fernandez-Fernandez R., Martini A, Navarro V., Castellano J, Dieguez C, Aguilar E., Pinilla L, Tena-Sempere M (2006) Novel signals for the integration of energy balance and reproduction. Mol Cell Endocrinol 254:127-132
29. Crown A, Clifton DK, Steiner R.A. (2007) Neuropeptide signaling in the integration of metabolism and reproduction. Neuroendocrinology 86(3):175-182
30. Arias P, Rodriguez M, Szwarcfarb B., Sinay I, Moguilevsky J. (1992) Effect of insulin on LHRH release by perifused hypotha-lamic fragments. Neuroendocrinology 56(3):415-418
31. Miller D, Blache D, Martin G. (1995) The role of intracerebral insulin in the effect of nutrition on gonadotrophin secretion in mature male sheep. J Endocrinol 147(2):321
32. Reaven G, Thompson L, Nahum D., Haskins E. (1990) Relationship between hyperglycemia and cognitive function in older NIDDM patients. Diabetes Care 13(1):16
33. Benedict C, Hallschmid M, Hatke A., Schultes B, Fehm HL, Born J, Kern W. (2004) Intranasal insulin improves memory in humans. Psychoneuroendocrinology 29(10):1326-1334
34. Babri S, Badie HG, Khamenei S, Ordikhani-Seyedlar M (2007) Intrahippocampal insulin improves memory in a passive-avoidance task in male wistar rats. Brain Cogn 64(1):86-91
35. Haj-ali V., Mohaddes G, Babri S. (2009) Intracerebroventricular insulin improves spatial learning and memory in male Wistar rats. Behav Neurosci 123(6):1309
36. Park CR, Seeley RJ, Craft S, Woods S.C. (2000) Intracerebroventricular insulin enhances memory in a passive-avoidance task. Physiol Behav 68(4):509-514
37. Kovacs P, Hajnal A. (2009) In vivo electrophysiological effects of insulin in the rat brain. Neuropeptides 43(4):283-293. doi:10.1016/j.npep.2009. 05.006
38. Palovcik RA, Phillips MI, Kappy M.S., Raizada M.K. (1984) Insulin inhibits pyramidal neurons in hippocampal slices. Brain Res 309(1):187-191
39. Wan Q, Xiong ZG, Man H.Y., Ackerley CA, Braunton J, Lu WY, Becker L.E., MacDonald JF, Wang YT (1997) Recruitment of functional GABA(A) receptors to postsynaptic domains by insulin. Nature 388(6643):686-690. doi:10.1038/41792
40. Lozovsky DB, Kopin IJ, Saller C.F. (1985) Modulation of dopa-mine receptor supersensitivity by chronic insulin: implication in schizophrenia. Brain Res 343(1):190-193
41. Fadool D, Tucker K, Phillips J., Simmen J. (2000) Brain insulin receptor causes activity-dependent current suppression in the olfactory bulb through multiple phosphorylation of Kv1. 3. J Neurophysiol 83(4):2332
42. Farrar C, Houser CR, Clarke S. (2005) Activation of the PI3K/Akt signal transduction pathway and increased levels of insulin receptor in protein repair-deficient mice. Aging Cell 4(1):1-12. doi:10.1111/j.1474-9728.2004.00136. x
43. Schubert M, Brazil D, Burks D., Kushner J, Ye J, Flint C., Farhang-Fallah J, Dikkes P, Warot X, Rio C (2003) Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phos-phorylation. J Neurosci Off J Soc Neurosci 23(18):7084
44. Ryu BR, Ko HW, Jou I, Noh J.S., Gwag B.J. (1999) Phosphatidylinositol 3-kinase-mediated regulation of neuronal apoptosis and necrosis by insulin and IGF-I. J Neurobiol 39(4):536-546. doi:10.1002/(SICI)1097-4695(19990615)39: 4<536::AID-NEU7>3.0.CO;2-J
45. Duarte AI, Santos MS, Oliveira C.R., Rego A.C. (2005) Insulin neuroprotection against oxidative stress in cortical neurons-involvement of uric acid and glutathione antioxidant defenses. Free Radic Biol Med 39(7):876-889
46. Rensink AA, Otte-Holler I, de Boer R, Bosch RR, ten Donkelaar HJ, de Waal RM, Verbeek MM, Kremer B (2004) Insulin inhibits amyloid beta-induced cell death in cultured human brain peri-cytes. Neurobiol Aging 25(1):93-103
47. Voll CL, Auer R.N. (1991) Insulin attenuates ischemic brain damage independent of its hypoglycemic effect. J Cereb Blood Flow Metab 11(6):1006-1014. doi:10.1038/jcbfm.1991.168
48. Holtzman DM, Morris JC, Goate A.M. (2011) Alzheimer's disease: the challenge of the second century. Sci Transl Med 3(77):77sr71. doi:10.1126/scitranslmed.3002369
49. Biessels GJ, Staekenborg S, Brunner E., Brayne C, Scheltens P. (2006) Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 5(1):64-74. doi:10.1016/S1474-4422(05)70284-2
50. Kuusisto J, Koivisto K, Mykkanen L., Helkala EL, Vanhanen M, Hanninen T, Kervinen K., Kesaniemi YA, Riekkinen PJ, Laakso M (1997) Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipopro-tein E4 phenotype: cross sectional population based study. BMJ 315(7115):1045-1049
51. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, Breteler M.M. (1999) Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 53(9):1937-1942
52. Schrijvers EM, Witteman JC, Sijbrands E.J., Hofman A., Koudstaal PJ, Breteler M.M. (2010) Insulin metabolism and the risk of Alzheimer disease: the Rotterdam Study. Neurology 75(22):1982-1987. doi:10.1212/WNL.0b013e3181ffe4f6
53. Akomolafe A, Beiser A, Meigs J.B., Au R., Green RC, Farrer LA, Wolf PA, Seshadri S. (2006) Diabetes mellitus and risk of developing Alzheimer disease: results from the Framingham Study. Arch Neurol 63(11):1551-1555. doi:10.1001/archneur.63.11.1551
54. Xu W, Qiu C, Winblad B., Fratiglioni L. (2007) The effect of borderline diabetes on the risk of dementia and Alzheimer's disease. Diabetes 56(1):211-216. doi:10.2337/db06-0879
55. Kalaria RN (2009) Neurodegenerative disease: diabetes, micro-vascular pathology and Alzheimer disease. Nat Rev Neurol 5(6):305-306. doi:10.1038/nrneurol.2009.72
56. Matsuzaki T, Sasaki K, Tanizaki Y., Hata J, Fujimi K, Matsui Y., Sekita A, Suzuki SO, Kanba S, Kiyohara Y, Iwaki T (2010) Insulin resistance is associated with the pathology of Alzheimer disease: the Hisayama study. Neurology 75(9):764-770. doi:10.1212/WNL.0b013e3181eee25f
57. MacKnight C, Rockwood K, Awalt E., McDowell I. (2002) Diabetes mellitus and the risk of dementia, Alzheimer's disease and vascular cognitive impairment in the Canadian Study of Health and Aging. Dement Geriatr Cogn Disord 14(2):77-83
58. Xu WL, Qiu CX, Wahlin A, Winblad B., Fratiglioni L. (2004) Diabetes mellitus and risk of dementia in the Kungsholmen project: a 6-year follow-up study. Neurology 63(7):1181-1186
59. Hassing LB, Johansson B, Nilsson S.E., Berg S., Pedersen NL, Gatz M, McClearn G. (2002) Diabetes mellitus is a risk factor for vascular dementia, but not for Alzheimer's disease: a population-based study of the oldest old. Int Psychogeriatr 14(3):239-248
60. Alafuzoff I, Aho L, Helisalmi S., Mannermaa A, Soininen H. (2009) Beta-amyloid deposition in brains of subjects with diabetes. Neuropathol Appl Neurobiol 35(1):60-68. doi:10.1111/j.1365-2990.2008.00948.x
61. Nielson KA, Nolan JH, Berchtold N.C., Sandman CA, Mulnard RA, Cotman C.W. (1996) Apolipoprotein-E genotyping of diabetic dementia patients: is diabetes rare in Alzheimer's disease? J Am Geriatr Soc 44(8):897-904
62. Arvanitakis Z, Schneider JA, Wilson R.S., Li Y., Arnold SE, Wang Z, Bennett D.A. (2006) Diabetes is related to cerebral infarction but not to AD pathology in older persons. Neurology 67(11):1960-1965. doi:10.1212/01.wnl. 0000247053.45483.4e
63. Craft S, Peskind E, Schwartz M.W., Schellenberg GD, Raskind M, Porte D Jr (1998) Cerebrospinal fluid and plasma insulin levels in Alzheimer's disease: relationship to severity of dementia and apolipoprotein E genotype. Neurology 50(1):164
64. Gil-Bea F.J., Solas M, Solomon A., Mugueta C, Winblad B, Kivipelto M., Ramirez MJ, Cedazo-Minguez A (2010) Insulin levels are decreased in the cerebrospinal fluid of women with prodomal Alzheimer's disease. J Alzheimers Dis 22(2):405-413. doi:10.3233/JAD-2010-100795
65. Takeda S, Sato N, Uchio-Yamada K, Sawada K., Kunieda T, Takeuchi D, Kurinami H., Shinohara M, Rakugi H, Morishita R (2010) Diabetes-accelerated memory dysfunction via cerebrovas-cular inflammation and Abeta deposition in an Alzheimer mouse model with diabetes. Proc Natl Acad Sci U S A 107(15):7036-7041. doi:10.1073/pnas.1000645107
66. Eikelenboom P, Veerhuis R, Scheper W., Rozemuller AJ, van Gool WA, Hoozemans JJ (2006) The significance of neuroinflammation in understanding Alzheimer's disease. J Neural Transm 113(11):1685-1695. doi:10.1007/s00702-006- 0575-6
67. Olefsky JM, Glass C.K. (2010) Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72:219-246. doi:10.1146/annurev-physiol-021909- 135846
68. Fukao T, Tanabe M, Terauchi Y., Ota T, Matsuda S, Asano T., Kadowaki T, Takeuchi T, Koyasu S (2002) PI3K-mediated negative feedback regulation of IL-12 production in DCs. Nat Immunol 3(9):875-881. doi:10.1038/ni825
69. Avila J, Wandosell F, Hernandez F. (2010) Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and gly-cogen synthase kinase-3 inhibitors. Expert Rev Neurother 10(5):703-710. doi:10.1586/ern.10.40
70. Balaraman Y, Limaye AR, Levey A.I., Srinivasan S. (2006) Glycogen synthase kinase 3beta and Alzheimer's disease: patho-physiological and therapeutic significance. Cell Mol Life Sci 63(11):1226-1235. doi:10.1007/s00018-005-5597-y
71. Cross DA, Alessi DR, Cohen P, Andjelkovich M., Hemmings B.A. (1995) Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B. Nature 378(6559):785-789. doi:10.1038/378785a0
72. Lee J, Kim M.S. (2007) The role of GSK3 in glucose homeostasis and the development of insulin resistance. Diabetes Res Clin Pract 77 (Suppl 1):S49-S57. doi:10.1016/j.diabres.2007.01.033
73. Beurel E, Jope R.S. (2008) Differential regulation of STAT family members by glycogen synthase kinase-3. J Biol Chem 283(32):21934-21944. doi:10.1074/jbc.M802481200
74. Martin M, Rehani K, Jope R.S., Michalek S.M. (2005) Toll-like receptor-mediated cytokine production is differentially regulated by glycogen synthase kinase 3. Nat Immunol 6(8):777-784. doi:10.1038/ni1221
75. Hu X, Paik PK, Chen J, Yarilina A., Kockeritz L, Lu TT, Woodgett J.R., Ivashkiv L.B. (2006) IFN-gamma suppresses IL-10 production and synergizes with TLR2 by regulating GSK3 and CREB/AP-1 proteins. Immunity 24(5):563-574. doi:10.1016/j.immuni.2006.02.014
76. Saberi M, Woods NB, de Luca C, Schenk S, Lu J.C., Bandyopadhyay G., Verma IM, Olefsky JM (2009) Hematopoietic cell-specific deletion of toll-like receptor 4 ameliorates hepatic and adipose tissue insulin resistance in high-fat-fed mice. Cell Metab 10(5):419-429. doi:10.1016/j.cmet.2009.09.006
77. Lee YS, Li P, Huh J.Y., Hwang IJ, Lu M, Kim JI, Ham M, Talukdar S., Chen A, Lu WJ, Bandyopadhyay GK, Schwendener R, Olefsky J, Kim JB (2011) Inflammation is necessary for long-term but not short-term high-fat diet-induced insulin resistance. Diabetes 60(10):2474-2483. doi:10.2337/db11-0194
78. Hotamisligil GS, Budavari A, Murray D., Spiegelman B.M. (1994) Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest 94(4):1543-1549. doi:10.1172/jci117495
79. Kalupahana NS, Moustaid-Moussa N (2012) The renin-angiotensin system: a link between obesity, inflammation and insulin resistance. Obesity Rev 13(2):136-149. doi:10.1111/j.1467-789X.2011.00942.x
80. Wellen KE, Hotamisligil G.S. (2005) Inflammation, stress, and diabetes. J Clin Invest 115(5):1111-1119. doi:10.1172/jci25102
81. Tu YF, Tsai YS, Wang L.W., Wu HC, Huang CC, Ho C.J. (2011) Overweight worsens apoptosis, neuroinflammation and blood-brain barrier damage after hypoxic ischemia in neonatal brain through JNK hyperactivation. J Neuroinflammation 8:40. doi:10.1186/1742-2094-8-40
82. Sartorius T, Lutz SZ, Hoene M, Waak J., Peter A, Weigert C, Rammensee H.G., Kahle PJ, Haring HU, Hennige AM (2012) Toll-like receptors 2 and 4 impair insulin-mediated brain activity by interleukin-6 and osteopontin and alter sleep architecture. FASEB J 26(5):1799-1809. doi:10.1096/fj.11-191023
83. Arruda AP, Milanski M, Coope A., Torsoni AS, Ropelle E, Carvalho DP, Carvalheira J.B., Velloso L.A. (2011) Low-grade hypothalamic inflammation leads to defective thermogenesis, insulin resistance, and impaired insulin secretion. Endocrinology 152(4):1314-1326. doi:10.1210/en.2010-0659
84. Konner AC, Bruning J.C. (2011) Toll-like receptors: linking inflammation to metabolism. Trends Endocrinol Metab TEM 22(1):16-23. doi:10.1016/j.tem.2010. 08.007
85. Frolich L, Blum-Degen D, Riederer P., Hoyer S. (1999) A disturbance in the neuronal insulin receptor signal transduction in sporadic Alzheimer's disease. Ann N Y Acad Sci 893:290-293
86. Steen E, Terry BM, Rivera E.J., Cannon JL, Neely TR, Tavares R, Xu X.J., Wands JR, de la Monte SM (2005) Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease-is this type 3 diabetes? J Alzheimers Dis 7(1):63-80
87. Zhao WQ, Lacor PN, Chen H, Lambert M.P., Quon MJ, Krafft GA, Klein W.L. (2009) Insulin receptor dysfunction impairs cellular clearance of neurotoxic oligomeric a{beta}. J Biol Chem 284(28):18742-18753. doi:10.1074/jbc.M109.011015
88. Xie L, Helmerhorst E, Taddei K., Plewright B, Van Bronswijk W, Martins R. (2002) Alzheimer's beta-amyloid peptides compete for insulin binding to the insulin receptor. J Neurosci 22(10):RC221
89. Lee HK, Kumar P, Fu Q., Rosen KM, Querfurth H.W. (2009) The insulin/Akt signaling pathway is targeted by intracellular beta-amyloid. Mol Biol Cell 20(5):1533-1544. doi:10.1091/mbc.E08-07-0777
90. Holscher C (2011) Diabetes as a risk factor for Alzheimer's disease: insulin signalling impairment in the brain as an alternative model of Alzheimer's disease. Biochem Soc Trans 39(4):891-897. doi:10.1042/BST0390891
91. de la Monte SM, Wands J.R. (2008) Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol 2(6):1101-1113
92. Lester-Coll N., Rivera EJ, Soscia S.J., Doiron K., Wands JR, de la Monte SM (2006) Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis 9(1):13-33
93. Grunblatt E, Hoyer S, Riederer P. (2004) Gene expression profile in streptozotocin rat model for sporadic Alzheimer's disease. J Neural Transm 111(3):367-386. doi:10.1007/s00702-003-0030-x
94. Hoyer S, Lee SK, Loffler T, Schliebs R. (2000) Inhibition of the neuronal insulin receptor. An in vivo model for sporadic Alzheimer disease? Ann N Y Acad Sci 920:256-258
95. de la Monte SM, Tong M, Lester-Coll N, Plater M Jr, Wands JR (2006) Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis 10(1):89-109
96. Craft S, Asthana S, Cook D.G., Baker LD, Cherrier M, Purganan K, Wait C., Petrova A, Latendresse S, Watson GS, Newcomer JW, Schellenberg GD, Krohn AJ (2003) Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: interactions with apolipoprotein E genotype. Psychoneuroendocrinology 28(6):809-822
97. Watson GS, Cholerton BA, Reger M.A., Baker LD, Plymate SR, Asthana S, Fishel M.A., Kulstad JJ, Green PS, Cook DG, Kahn SE, Keeling ML, Craft S (2005) Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: a preliminary study. Am J Geriatr Psychiatry 13(11):950-958. doi:10.1176/appi.ajgp.13.11.950
98. Risner ME, Saunders AM, Altman J.F., Ormandy GC, Craft S, Foley IM, Zvartau-Hind ME, Hosford D.A., Roses A.D. (2006) Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease. Pharmacogenomics J 6(4):246-254. doi:10.1038/sj.tpj.6500369
99. Pedersen WA, McMillan PJ, Kulstad J.J., Leverenz JB, Craft S, Haynatzki G.R. (2006) Rosiglitazone attenuates learning and memory deficits in Tg2576 Alzheimer mice. Exp Neurol 199(2):265-273. doi:10.1016/j.expneurol.2006.01.018
100. Jiang LH, Zhang YN, Wu X.W., Song FF, Guo D.Y. (2008) Effect of insulin on the cognizing function and expression of hippocam-pal Abeta1-40 of rat with Alzheimer disease. Chin Med J (Engl) 121(9):827-831
101. Zhao WQ, Townsend M. (2009) Insulin resistance and amyloido-genesis as common molecular foundation for type 2 diabetes and Alzheimer's disease. Biochim Biophys Acta 1792(5):482-496. doi:10.1016/j.bbadis.2008.10.014
102. Finder VH, Glockshuber R. (2007) Amyloid-beta aggregation. Neurodegener Dis 4(1):13-27. doi:10.1159/000100355
103. O'Brien T.D., Butler PC, Westermark P, Johnson K.H. (1993) Islet amyloid polypeptide: a review of its biology and potential roles in the pathogenesis of diabetes mellitus. Vet Pathol 30(4):317-332
104. Janson J, Ashley RH, Harrison D, McIntyre S., Butler P.C. (1999) The mechanism of islet amyloid polypeptide toxicity is membrane disruption by intermediate-sized toxic amyloid particles. Diabetes 48(3):491-498
105. Janson J, Laedtke T, Parisi J.E., O'Brien P, Petersen RC, Butler P.C. (2004) Increased risk of type 2 diabetes in Alzheimer disease. Diabetes 53(2):474-481
106. Shpund S, Gershon D. (1997) Alterations in the chaperone activity of HSP70 in aging organisms. Arch Gerontol Geriatr 24(2):125-131
107. Blake MJ, Udelsman R, Feulner G.J., Norton DD, Holbrook N.J. (1991) Stress-induced heat shock protein 70 expression in adrenal cortex: an adrenocorticotropic hormone-sensitive, age-dependent response. Proc Natl Acad Sci U S A 88(21):9873-9877
108. Buoso E, Lanni C, Schettini G., Govoni S, Racchi M. (2010) beta-Amyloid precursor protein metabolism: focus on the functions and degradation of its intracellular domain. Pharmacol Res 62(4):308-317. doi:10.1016/j.phrs.2010.05. 002
109. Bernstein HG, Ansorge S, Riederer P., Reiser M, Frolich L, Bogerts B. (1999) Insulin-degrading enzyme in the Alzheimer's disease brain: prominent localization in neurons and senile plaques. Neurosci Lett 263 (2-3):161-164
110. Qiu WQ, Walsh DM, Ye Z, Vekrellis K., Zhang J, Podlisny MB, Rosner M.R., Safavi A., Hersh LB, Selkoe DJ (1998) Insulin-degrading enzyme regulates extracellular levels of amyloid beta-protein by degradation. J Biol Chem 273 (49):32730-32738
111. Selkoe DJ (2001) Clearing the brain's amyloid cobwebs. Neuron 32(2):177-180
112. Li ZG, Zhang W, Sima A.A. (2007) Alzheimer-like changes in rat models of spontaneous diabetes. Diabetes 56(7):1817-1824. doi:10.2337/db07-0171
113. Ho L, Qin W, Pompl P.N., Xiang Z., Wang J, Zhao Z, Peng Y., Cambareri G, Rocher A, Mobbs CV, Hof PR, Pasinetti GM (2004) Diet-induced insulin resistance promotes amyloidosis in a transgenic mouse model of Alzheimer's disease. FASEB J 18(7):902-904. doi:10.1096/fj.03-0978fje
114. Farris W, Mansourian S, Chang Y., Lindsley L, Eckman EA, Frosch M.P., Eckman CB, Tanzi RE, Selkoe DJ, Guenette S (2003) Insulin-degrading enzyme regulates the levels of insulin, amyloid betaprotein, and the beta-amyloid precursor protein intracellular domain in vivo. Proc Natl Acad Sci U S A 100(7):4162-4167. doi:10.1073/pnas.0230450100
115. Shiiki T, Ohtsuki S, Kurihara A., Naganuma H, Nishimura K, Tachikawa M., Hosoya K, Terasaki T (2004) Brain insulin impairs amyloid-beta(1-40) clearance from the brain. J Neurosci 24(43):9632-9637. doi:10.1523/JNEUROSCI.2236-04.2004
116. Gasparini L, Gouras GK, Wang R, Gross R.S., Beal MF, Greengard P, Xu H. (2001) Stimulation of beta-amyloid precursor protein trafficking by insulin reduces intraneuronal beta-amyloid and requires mitogen-activated protein kinase signaling. J Neurosci 21(8):2561-2570
117. Zhao L, Teter B, Morihara T., Lim GP, Ambegaokar SS, Ubeda OJ, Frautschy S.A., Cole G.M. (2004) Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci 24(49):11120-11126. doi:10.1523/JNEUROSCI.2860-04.2004
118. Solano DC, Sironi M, Bonfini C., Solerte SB, Govoni S, Racchi M. (2000) Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway. FASEB J 14(7):1015-1022
119. Phiel CJ, Wilson CA, Lee V.M., Klein P.S. (2003) GSK-3alpha regulates production of Alzheimer's disease amyloid-beta pepti-des. Nature 423(6938):435-439. doi:10.1038/nature01640
120. Johnson GV (2006) Tau phosphorylation and proteolysis: insights and perspectives. J Alzheimers Dis 9 (3 Suppl):243-250
121. Chung CW, Song YH, Kim I.K., Yoon WJ, Ryu BR, Jo DG, Woo H.N., Kwon YK, Kim HH, Gwag BJ, Mook-Jung IH, Jung YK (2001) Proapoptotic effects of tau cleavage product generated by caspase-3. Neurobiol Dis 8(1):162-172. doi:10.1006/nbdi.2000.0335
122. Cotman CW, Poon WW, Rissman R.A., Blurton-Jones M (2005) The role of caspase cleavage of tau in Alzheimer disease neuro-pathology. J Neuropathol Exp Neurol 64(2):104-112
123. Rissman RA, Poon WW, Blurton-Jones M, Oddo S., Torp R, Vitek MP, LaFerla F.M., Rohn TT, Cotman CW (2004) Caspase-cleavage of tau is an early event in Alzheimer disease tangle pathology. J Clin Invest 114(1):121-130. doi:10.1172/jci20640
124. Kim B, Backus C, Oh S., Hayes JM, Feldman E.L. (2009) Increased tau phosphorylation and cleavage in mouse models of type 1 and type 2 diabetes. Endocrinology 150(12):5294-5301. doi:10.1210/en.2009-0695
125. Clodfelder-Miller B.J., Zmijewska AA, Johnson G.V., Jope R.S. (2006) Tau is hyperphosphorylated at multiple sites in mouse brain in vivo after streptozotocin-induced insulin deficiency. Diabetes 55(12):3320-3325. doi:10.2337/db06-0485
126. Planel E, Tatebayashi Y, Miyasaka T., Liu L, Wang L, Herman M., Yu WH, Luchsinger JA, Wadzinski B, Duff KE, Takashima A (2007) Insulin dysfunction induces in vivo tau hyperphosphory-lation through distinct mechanisms. J Neurosci 27(50):13635-13648. doi:10.1523/JNEUROSCI.3949-07.2007
127. Hong M, Lee V.M. (1997) Insulin and insulin-like growth factor-1 regulate tau phosphorylation in cultured human neurons. J Biol Chem 272(31):19547-19553
128. Jolivalt CG, Lee CA, Beiswenger K.K., Smith JL, Orlov M, Torrance MA, Masliah E. (2008) Defective insulin signaling pathway and increased glycogen synthase kinase-3 activity in the brain of diabetic mice: parallels with Alzheimer's disease and correction by insulin. J Neurosci Res 86(15):3265-3274. doi:10.1002/jnr.21787
129. Freude S, Plum L, Schnitker J., Leeser U, Udelhoven M, Krone W., Bruning JC, Schubert M (2005) Peripheral hyperinsulinemia promotes tau phosphorylation in vivo. Diabetes 54(12):3343-3348
130. Schechter R, Beju D, Miller K.E. (2005) The effect of insulin deficiency on tau and neurofilament in the insulin knockout mouse. Biochem Biophys Res Commun 334(4):979-986. doi:10.1016/j.bbrc.2005.07.001
131. Schubert M, Gautam D, Surjo D., Ueki K, Baudler S, Schubert D., Kondo T, Alber J, Galldiks N, Kustermann E, Arndt S, Jacobs AH, Krone W, Kahn CR, Bruning JC (2004) Role for neuronal insulin resistance in neurodegenerative diseases. Proc Natl Acad Sci U S A 101(9):3100-3105. doi:10.1073/pnas.0308724101
132. Schubert M, Brazil DP, Burks D.J., Kushner JA, Ye J, Flint CL, Farhang-Fallah J, Dikkes P., Warot XM, Rio C, Corfas G, White MF (2003) Insulin receptor substrate-2 deficiency impairs brain growth and promotes tau phosphorylation. J Neurosci 23 (18):7084-7092
133. Neumann KF, Rojo L, Navarrete L.P., Farias G., Reyes P, Maccioni R.B. (2008) Insulin resistance and Alzheimer's disease: molecular links and clinical implications. Curr Alzheimer Res 5(5):438-447
134. Reddy VP, Zhu X, Perry G., Smith M.A. (2009) Oxidative stress in diabetes and Alzheimer's disease. J Alzheimers Dis 16(4):763-774. doi:10.3233/JAD-2009- 1013
135. Moreira PI, Santos MS, Seica R, Oliveira C.R. (2007) Brain mitochondrial dysfunction as a link between Alzheimer's disease and diabetes. J Neurol Sci 257 (1-2):206-214. doi:10.1016/j.jns.2007.01.017
136. de la Monte SM, Wands J.R. (2006) Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J Alzheimers Dis 9(2):167-181
137. Coskun P, Wyrembak J, Schriner S., Chen HW, Marciniack C, Laferla F, Wallace D.C. (2011) A mitochondrial etiology of Alzheimer and Parkinson disease. Biochim Biophys Acta. doi:10.1016/j.bbagen.2011.08.008
138. Moreira PI, Duarte AI, Santos M.S., Rego AC, Oliveira C.R. (2009) An integrative view of the role of oxidative stress, mitochondria and insulin in Alzheimer's disease. J Alzheimers Dis 16(4):741-761. doi:10.3233/JAD-2009-0972
139. Reddy PH, Beal M.F. (2005) Are mitochondria critical in the pathogenesis of Alzheimer's disease? Brain Res Brain Res Rev 49(3):618-632. doi:10.1016/j.brainresrev.2005.03.004
140. Moreira PI, Carvalho C, Zhu X., Smith MA, Perry G. (2010) Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochim Biophys Acta 1802(1):2-10. doi:10.1016/j.bbadis.2009.10.006
141. Moreira PI, Cardoso SM, Santos M.S., Oliveira C.R. (2006) The key role of mitochondria in Alzheimer's disease. J Alzheimers Dis 9(2):101-110
142. Huang TJ, Price SA, Chilton L, Calcutt N.A., Tomlinson DR, Verkhratsky A, Fernyhough P. (2003) Insulin prevents depolarization of the mitochondrial inner membrane in sensory neurons of type 1 diabetic rats in the presence of sustained hyperglycemia. Diabetes 52(8):2129-2136
143. Moreira PI, Santos MS, Sena C, Seica R., Oliveira C.R. (2005) Insulin protects against amyloid beta-peptide toxicity in brain mitochondria of diabetic rats. Neurobiol Dis 18(3):628-637. doi:10.1016/j.nbd.2004.10.017
144. Dias WB, Hart G.W. (2007) O-GlcNAc modification in diabetes and Alzheimer's disease. Mol Biosyst 3(11):766-772. doi:10.1039/b704905f
145. Liu F, Iqbal K, Grundke-Iqbal I, Hart G.W., Gong C.X. (2004) O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease. Proc Natl Acad Sci U S A 101(29):10804-10809. doi:10.1073/pnas.0400348101
146. Liu F, Shi J, Tanimukai H., Gu J, Grundke-Iqbal I, Iqbal K, Gong C.X. (2009) Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease. Brain 132 (Pt 7):1820-1832. doi:10.1093/brain/awp099
147. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K., Gong C.X. (2009) Brain glucose transporters, O-GlcNAcylation and phosphorylation of tau in diabetes and Alzheimer's disease. J Neurochem 111(1):242-249. doi:10.1111/j.1471-4159.2009. 06320.x
148. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K., Gong C.X. (2011) Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J Pathol 225(1):54-62. doi:10.1002/path.2912
149. Hoyer S, Henneberg N, Knapp S., Lannert H, Martin E. (1996) Brain glucose metabolism is controlled by amplification and desensitization of the neuronal insulin receptors. Ann N Y Acad Sci 777(1):374-379
150. Craft S, Dagogo-Jack SE, Wiethop B.V., Murphy C., Nevins RT, Fleischman S, Rice V, Newcomer J.W., Cryer P.E. (1993) Effects of hyperglycemia on memory and hormone levels in dementia of the Alzheimer type: a longitudinal study. Behav Neurosci 107 (6):926-940
151. Craft S, Zallen G, Baker L.D. (1992) Glucose and memory in mild senile dementia of the Alzheimer type. J Clin Exp Neuropsychol 14(2):253-267. doi:10.1080/01688639208402827
152. Manning CA, Ragozzino ME, Gold P.E. (1993) Glucose enhancement of memory in patients with probable senile dementia of the Alzheimer's type. Neurobiol Aging 14(6):523-528
153. Mosconi L, Tsui WH, Herholz K, Pupi A., Drzezga A, Lucignani G, Reiman E.M., Holthoff V., Kalbe E, Sorbi S, Diehl-Schmid J, Perneczky R, Clerici F, Caselli R, Beuthien-Baumann B, Kurz A, Minoshima S, de Leon MJ (2008) Multicenter standardized 18F-FDG PET diagnosis of mild cognitive impairment, Alzheimer's disease, and other dementias. J Nucl Med 49(3):390-398. doi:10.2967/jnumed.107.045385
154. Friedland RP, Budinger TF, Koss E, Ober B.A. (1985) Alzheimer's disease: anterior-posterior and lateral hemispheric alterations in cortical glucose utilization. Neurosci Lett 53(3):235-240
155. Craft S, Newcomer J, Kanne S., Dagogo-Jack S, Cryer P, Sheline Y., Luby J, Dagogo-Jack A, Alderson A (1996) Memory improvement following induced hyperinsulinemia in Alzheimer's disease. Neurobiol Aging 17(1):123-130
156. Craft S, Asthana S, Newcomer J.W., Wilkinson CW, Matos IT, Baker LD, Cherrier M, Lofgreen C., Latendresse S, Petrova A, Plymate S, Raskind M, Grimwood K, Veith RC (1999) Enhancement of memory in Alzheimer disease with insulin and somatostatin, but not glucose. Arch Gen Psychiatry 56(12):1135-1140
157. Brunham LR, Kruit JK, Verchere C.B., Hayden M.R. (2008) Cholesterol in islet dysfunction and type 2 diabetes. J Clin Invest 118(2):403-408. doi:10.1172/JCI33296
158. Osborne AR, Pollock VV, Lagor W.R., Ness G.C. (2004) Identification of insulin-responsive regions in the HMG-CoA reductase promoter. Biochem Biophys Res Commun 318(4):814-818. doi:10.1016/j.bbrc.2004.04.105
159. Hoyer S (2004) Glucose metabolism and insulin receptor signal transduction in Alzheimer disease. Eur J Pharmacol 490 (1-3):115-125. doi:10.1016/j.ejphar.2004.02.049
160. Evans RM, Hui S, Perkins A., Lahiri DK, Poirier J, Farlow M.R. (2004) Cholesterol and APOE genotype interact to influence Alzheimer disease progression. Neurology 62(10):1869-1871
161. Petanceska SS, DeRosa S, Olm V., Diaz N, Sharma A, Thomas-Bryant T, Duff K., Pappolla M, Refolo LM (2002) Statin therapy for Alzheimer's disease: will it work? J Mol Neurosci 19(1-2):155-161. doi:10.1007/s12031-002-0026-2
162. Wolozin B, Kellman W, Ruosseau P., Celesia GG, Siegel G. (2000) Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors. Arch Neurol 57(10):1439-1443
163. Eckert GP, Kirsch C, Leutz S., Wood WG, Muller W.E. (2003) Cholesterol modulates amyloid beta-peptide's membrane interactions. Pharmacopsychiatry 36 (Suppl 2):S136-S143. doi:10.1055/s-2003-43059
164. Nelson TJ, Alkon D.L. (2005) Insulin and cholesterol pathways in neuronal function, memory and neurodegeneration. Biochem Soc Trans 33 (Pt 5):1033-1036. doi:10.1042/BST20051033
165. Nelson TJ, Alkon D.L. (2005) Oxidation of cholesterol by amyloid precursor protein and beta-amyloid peptide. J Biol Chem 280(8):7377-7387. doi:10.1074/jbc.M409071200
166. Puglielli L, Tanzi RE, Kovacs D.M. (2003) Alzheimer's disease: the cholesterol connection. Nat Neurosci 6(4):345-351. doi:10.1038/nn0403-345
167. Dehay B, Bezard E. (2011) New animal models of Parkinson's disease. Mov Disord 26(7):1198-1205
168. Unger JW, Livingston JN, Moss A.M. (1991) Insulin receptors in the central nervous system: localization, signalling mechanisms and functional aspects. Prog Neurobiol 36(5):343-362
169. Figlewicz DP, Evans SB, Murphy J, Hoen M., Baskin D.G. (2003) Expression of receptors for insulin and leptin in the ventral tegmental area/substantia nigra (VTA/SN) of the rat. Brain Res 964(1):107-115
170. Moroo I, Yamada T, Makino H., Tooyama I, McGeer PL, McGeer E.G., Hirayama K. (1994) Loss of insulin receptor immunoreactiv-ity from the substantia nigra pars compacta neurons in Parkinson's disease. Acta Neuropathol 87(4):343-348
171. Takahashi M, Yamada T, Tooyama I., Moroo I, Kimura H, Yamamoto T., Okada H. (1996) Insulin receptor mRNA in the substantia nigra in Parkinson's disease. Neurosci Lett 204(3):201-204
172. Sandyk R (1993) The relationship between diabetes mellitus and Parkinson's disease. Int J Neurosci 69 (1-4):125-130
173. Kuranuki S, Arai C, Terada S., Aoyama T, Nakamura T. (2011) Possible regulatory factors for intra-abdominal fat mass in a rat model of Parkinson's disease. Nutrition 27(2):239-243. doi:10.1016/j.nut.2009.12.002
174. Wilhelm KR, Yanamandra K, Gruden M.A., Zamotin V., Malisauskas M, Casaite V, Darinskas A., Forsgren L, Morozova-Roche LA (2007) Immune reactivity towards insulin, its amyloid and protein S100B in blood sera of Parkinson's disease patients. Eur J Neurol 14(3):327-334. doi:10.1111/j.1468-1331.2006.01667.x
175. Arvanitakis Z, Wilson RS, Bienias J.L., Bennett D.A. (2007) Diabetes and parkinsonian signs in older persons. Alzheimer Dis Assoc Disord 21(2):144-149. doi:10.1097/WAD.0b013e31805ba768
176. Xu Q, Park Y, Huang X., Hollenbeck A, Blair A, Schatzkin A., Chen H. (2011) Diabetes and risk of Parkinson's disease. Diabetes Care 34(4):910-915. doi:10.2337/dc10-1922
177. Schernhammer E, Hansen J, Rugbjerg K., Wermuth L, Ritz B. (2011) Diabetes and the risk of developing Parkinson's disease in Denmark. Diabetes Care 34(5):1102-1108. doi:10.2337/dc10-1333
178. Driver JA, Smith A, Buring J.E., Gaziano JM, Kurth T, Logroscino G. (2008) Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. Diabetes Care 31(10):2003-2005. doi:10.2337/dc08-0688
179. Jimenez-Jimenez F.J., Molina JA, Vargas C, Gomez P., De Bustos F, Zurdo M, Gomez-Escalonilla C, Barcenilla B., Berbel A, Camacho A, Arenas J (2000) Normal cerebrospinal fluid levels of insulin in patients with Parkinson's disease. J Neural Transm 107(4):445-449
180. Vroon A, Drukarch B, Bol J.G., Cras P., Breve JJ, Allan SM, Relton JK, Hoogland P.V., Van Dam AM (2007) Neuroinflammation in Parkinson's patients and MPTP-treated mice is not restricted to the nigrostriatal system: microgliosis and differential expression of interleukin-1 receptors in the olfactory bulb. Exp Gerontol 42(8):762-771. doi:10.1016/j.exger.2007.04.010
181. Depino AM, Earl C, Kaczmarczyk E., Ferrari C, Besedovsky H, del Rey A, Pitossi FJ, Oertel WH (2003) Microglial activation with atypical proinflammatory cytokine expression in a rat model of Parkinson's disease. Eur J Neurosci 18(10):2731-2742
182. He Y, Appel S, Le W. (2001) Minocycline inhibits microglial activation and protects nigral cells after 6-hydroxydopamine injection into mouse striatum. Brain Res 909 (1-2):187-193
183. Gao HM, Kotzbauer PT, Uryu K, Leight S., Trojanowski JQ, Lee V.M. (2008) Neuroinflammation and oxidation/nitration of alpha-synuclein linked to dopaminergic neurodegeneration. J Neurosci 28(30):7687-7698. doi:10.1523/jneurosci.0143-07.2008
184. Tseng YT, Hsu YY, Shih Y.T., Lo Y.C. (2012) Paeonol attenuates microglia-mediated inflammation and oxidative stress-induced neurotoxicity in rat primary microglia and cortical neurons. Shock (Augusta, Ga) 37(3):312-318. doi:10.1097/SHK.0b013e31823fe939
185. Hirsch EC, Hunot S. (2009) Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol 8(4):382-397. doi:10.1016/s1474- 4422(09)70062-6
186. Qian L, Flood PM, Hong J.S. (2010) Neuroinflammation is a key player in Parkinson's disease and a prime target for therapy. J Neural Transm 117(8):971-979. doi:10.1007/s00702-010-0428-1
187. Swanson CR, Joers V, Bondarenko V., Brunner K, Simmons HA, Ziegler T.E., Kemnitz JW, Johnson JA, Emborg ME (2011) The PPAR-gamma agonist pioglitazone modulates inflammation and induces neuroprotection in parkinsonian monkeys. J Neuroinflammation 8:91. doi:10.1186/1742-2094-8-91
188. Morris JK, Bomhoff GL, Gorres B.K., Davis VA, Kim J, Lee PP, Brooks W.M., Gerhardt GA, Geiger PC, Stanford JA (2011) Insulin resistance impairs nigrostriatal dopamine function. Exp Neurol 231(1):171-180. doi:10.1016/j. expneurol.2011.06.005
189. Saller CF (1984) Dopaminergic activity is reduced in diabetic rats. Neurosci Lett 49(3):301-306
190. Murzi E, Contreras Q, Teneud L., Valecillos B, Parada MA, De Parada MP, Hernandez L (1996) Diabetes decreases limbic extracellular dopamine in rats. Neurosci Lett 202(3):141-144
191. Morris JK, Bomhoff GL, Stanford J.A., Geiger P.C. (2010) Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet. Am J Physiol Regul Integr Comp Physiol 299(4):R1082-R1090. doi:10.1152/ajpregu.00449.2010
192. Daubner SC, Le T, Wang S. (2011) Tyrosine hydroxylase and regulation of dopamine synthesis. Arch Biochem Biophys 508(1):1-12. doi:10.1016/j.abb.2010.12. 017
193. Figlewicz DP, Brot MD, McCall A.L., Szot P. (1996) Diabetes causes differential changes in CNS noradrenergic and dopaminergic neurons in the rat: a molecular study. Brain Res 736 (1-2):54-60
194. Kono T, Takada M. (1994) Dopamine depletion in nigrostria-tal neurons in the genetically diabetic rat. Brain Res 634 (1):155-158
195. Figlewicz DP, Szot P, Israel P.A., Payne C., Dorsa D.M. (1993) Insulin reduces norepinephrine transporter mRNA in vivo in rat locus coeruleus. Brain Res 602(1):161-164
196. Figlewicz DP, Szot P, Chavez M., Woods SC, Veith R.C. (1994) Intraventricular insulin increases dopamine transporter mRNA in rat VTA/substantia nigra. Brain Res 644(2):331-334
197. Liu Z, Wang Y, Zhao W., Ding J, Mei Z, Guo L., Cui D, Fei J (2001) Peptide derived from insulin with regulatory activity of dopamine transporter. Neuropharmacology 41(4):464-471
198. Patterson TA, Brot MD, Zavosh A, Schenk J.O., Szot P., Figlewicz D.P. (1998) Food deprivation decreases mRNA and activity of the rat dopamine transporter. Neuroendocrinology 68(1):11-20
199. Colin E, Regulier E, Perrin V., Durr A, Brice A, Aebischer P., Deglon N, Humbert S, Saudou F (2005) Akt is altered in an animal model of Huntington's disease and in patients. Eur J Neurosci 21(6):1478-1488. doi:10.1111/j.1460- 9568.2005.03985.x
200. Hashimoto K, Ito Y, Tanahashi H., Hayashi M, Yamakita N, Yasuda K. (2012) Hyperglycemic chorea-ballism or acute exacerbation of Huntington's chorea? Huntington's disease unmasked by diabetic ketoacidosis in type 1 diabetes mellitus. J Clin Endocrinol Metab 97(9):3016-3020. doi:10.1210/jc.2012-1190
201. Boesgaard TW, Nielsen TT, Josefsen K, Hansen T., Jorgensen T, Pedersen O, Norremolle A., Nielsen JE, Hasholt L (2009) Huntington's disease does not appear to increase the risk of diabetes mellitus. J Neuroendocrinol 21(9):770-776. doi:10.1111/j.1365-2826.2009.01898.x
202. Hsiao HY, Chern Y. (2010) Targeting glial cells to elucidate the pathogenesis of Huntington's disease. Mol Neurobiol 41 (2-3):248-255. doi:10.1007/s12035-009-8097-5
203. Napolitano M, Costa L, Palermo R., Giovenco A, Vacca A, Gulino A. (2011) Protective effect of pioglitazone, a PPARgamma ligand, in a 3 nitropropionic acid model of Huntington's disease. Brain Res Bull 85 (3-4):231-237. doi:10.1016/j.brainresbull.2011.03.011
204. Kalonia H, Kumar A. (2011) Suppressing inflammatory cascade by cyclo-oxygenase inhibitors attenuates quinolinic acid induced Huntington's disease-like alterations in rats. Life Sci 88 (17-18):784-791. doi:10.1016/j.lfs.2011.02.020
205. Soulet D, Cicchetti F. (2011) The role of immunity in Huntington's disease. Mol Psychiatry 16(9):889-902. doi:10.1038/mp.2011.28
206. Farrer LA (1985) Diabetes mellitus in Huntington disease. Clin Genet 27(1):62-67
207. Podolsky S, Leopold NA, Sax D.S. (1972) Increased frequency of diabetes mellitus in patients with Huntington's chorea. Lancet 1 (7765):1356-1358
208. Podolsky S, Leopold N.A. (1977) Abnormal glucose tolerance and arginine tolerance tests in Huntington's disease. Gerontology 23 (1):55-63
209. Bjorkqvist M, Fex M, Renstrom E., Wierup N, Petersen A, Gil J., Bacos K, Popovic N, Li JY, Sundler F, Brundin P, Mulder H (2005) The R6/2 transgenic mouse model of Huntington's disease develops diabetes due to deficient beta-cell mass and exocytosis. Hum Mol Genet 14(5):565-574. doi:10.1093/hmg/ddi053
210. Smith R, Bacos K, Fedele V., Soulet D, Walz HA, Obermuller S, Lindqvist A., Bjorkqvist M, Klein P, Onnerfjord P, Brundin P, Mulder H, Li JY (2009) Mutant huntingtin interacts with {beta}-tubulin and disrupts vesicular transport and insulin secretion. Hum Mol Genet 18(20):3942-3954. doi:10.1093/hmg/ddp336
211. Andreassen OA, Dedeoglu A, Stanojevic V., Hughes DB, Browne SE, Leech CA, Ferrante R.J., Habener JF, Beal MF, Thomas MK (2002) Huntington's disease of the endocrine pancreas: insulin deficiency and diabetes mellitus due to impaired insulin gene expression. Neurobiol Dis 11(3):410-424
212. Hurlbert MS, Zhou W, Wasmeier C., Kaddis FG, Hutton JC, Freed C.R. (1999) Mice transgenic for an expanded CAG repeat in the Huntington's disease gene develop diabetes. Diabetes 48(3):649-651
213. Hunt MJ, Morton A.J. (2005) Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents. Exp Brain Res Experimentelle Hirnforschung Experimentation Cerebrale 166(2):220-229. doi:10.1007/s00221-005-2357-z
214. Lalic NM, Maric J, Svetel M., Jotic A, Stefanova E, Lalic K., Dragasevic N, Milicic T, Lukic L, Kostic VS (2008) Glucose homeostasis in Huntington disease: abnormalities in insulin sensitivity and early-phase insulin secretion. Arch Neurol 65(4):476-480. doi:10.1001/archneur.65.4.476
215. Duarte AI, Petit GH, Ranganathan S, Li J.Y., Oliveira CR, Brundin P, Bjorkqvist M, Rego A.C. (2011) IGF-1 protects against diabetic features in an in vivo model of Huntington's disease. Exp Neurol 231(2):314-319. doi:10.1016/j.expneurol.2011.06.016
216. Gamberino WC, Brennan WA Jr (1994) Glucose transporter isoform expression in Huntington's disease brain. J Neurochem 63 (4):1392-1397
217. Cardoso S, Correia S, Santos R.X., Carvalho C., Santos MS, Oliveira CR, Perry G, Smith M.A., Zhu X., Moreira P.I. (2009) Insulin is a two-edged knife on the brain. J Alzheimers Dis 18(3):483-507. doi:10.3233/jad-2009-1155
218. Crocker SF, Costain WJ, Robertson H.A. (2006) DNA microarray analysis of striatal gene expression in symptomatic transgenic Huntington's mice (R6/2) reveals neuroinflammation and insulin associations. Brain Res 1088(1):176-186. doi:10.1016/j.brainres.2006.02.102
219. Humbert S, Bryson EA, Cordelieres F.P., Connors NC, Datta SR, Finkbeiner S, Greenberg M.E., Saudou F. (2002) The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell 2(6):831-837
220. Yamamoto A, Cremona ML, Rothman J.E. (2006) Autophagy-mediated clearance of huntingtin aggregates triggered by the insulin-signaling pathway. J Cell Biol 172(5):719-731. doi:10.1083/jcb.200510065
221. Reichel A, Schwarz J, Schulze J., Licinio J, Wong ML, Bornstein S.R. (2005) Depression and anxiety symptoms in diabetic patients on continuous subcutaneous insulin infusion (CSII). Mol Psychiatry 10(11):975-976. doi:10.1038/sj.mp.4001726
222. Knol MJ, Twisk JW, Beekman A.T., Heine RJ, Snoek FJ, Pouwer F. (2006) Depression as a risk factor for the onset of type 2 diabetes mellitus. A meta-analysis. Diabetologia 49(5):837-845. doi:10.1007/s00125-006-0159-x
223. Pan A, Lucas M, Sun Q., van Dam RM, Franco OH, Manson JE, Willett WC, Ascherio A, Hu F.B. (2010) Bidirectional association between depression and type 2 diabetes mellitus in women. Arch Intern Med 170(21):1884-1891. doi:10.1001/archinternmed.2010.356
224. Pearson S, Schmidt M, Patton G., Dwyer T, Blizzard L, Otahal P., Venn A. (2010) Depression and insulin resistance: cross-sectional associations in young adults. Diabetes Care 33(5):1128-1133. doi:10.2337/dc09-1940
225. Shomaker LB, Tanofsky-Kraff M, Young-Hyman D, Han JC, Yanoff L.B., Brady SM, Yanovski SZ, Yanovski JA (2010) Psychological symptoms and insulin sensitivity in adolescents. Pediatr Diabetes 11(6):417-423. doi:10.1111/j.1399- 5448.2009.00606.x
226. Grey M, Whittemore R, Tamborlane W. (2002) Depression in type 1 diabetes in children: natural history and correlates. J Psychosom Res 53(4):907-911
227. Timonen M, Rajala U, Jokelainen J., Keinanen-Kiukaanniemi S, Meyer-Rochow VB, Rasanen P. (2006) Depressive symptoms and insulin resistance in young adult males: results from the Northern Finland 1966 birth cohort. Mol Psychiatry 11(10):929-933. doi:10.1038/sj.mp.4001838
228. Pan A, Ye X, Franco O.H., Li H., Yu Z, Zou S, Zhang Z., Jiao S, Lin X (2008) Insulin resistance and depressive symptoms in middle-aged and elderly Chinese: findings from the Nutrition and Health of Aging Population in China Study. J Affect Disord 109 (1-2):75-82. doi:10.1016/j.jad.2007.11.002
229. Potyralska MM, Krawczyk A.K. (2007) Depression in patients with type 2 diabetes mellitus-clinical and therapeutical implications. Wiad Lek 60 (9-10):449-453
230. Kivimaki M, Tabak AG, Lawlor D.A., Batty GD, Singh-Manoux A, Jokela M, Virtanen M., Salo P, Oksanen T, Pentti J, Witte DR, Vahtera J (2010) Antidepressant use before and after the diagnosis of type 2 diabetes: a longitudinal modeling study. Diabetes Care 33(7):1471-1476. doi:10.2337/dc09- 2359
231. Chen TH, Lan TH, Yang C.Y., Juang K.D. (2006) Postpartum mood disorders may be related to a decreased insulin level after delivery. Med Hypotheses 66(4):820-823. doi:10.1016/j.mehy.2005.09.032
232. Miyata S, Hirano S, Kamei J. (2004) Diabetes attenuates the antidepressant-like effect mediated by the activation of 5-HT1A receptor in the mouse tail suspension test. Neuropsychopharmacology 29(3):461-469. doi:10.1038/sj.npp.1300354
233. Anderson RJ, Freedland KE, Clouse R.E., Lustman P.J. (2001) The prevalence of comorbid depression in adults with diabetes: a meta-analysis. Diabetes Care 24(6):1069-1078
234. de Groot M., Anderson R, Freedland K.E., Clouse RE, Lustman P.J. (2001) Association of depression and diabetes complications: a meta-analysis. Psychosom Med 63(4):619-630
235. Ali S, Stone MA, Peters J.L., Davies MJ, Khunti K. (2006) The prevalence of co-morbid depression in adults with type 2 diabetes: a systematic review and meta-analysis. Diabet Med 23(11):1165-1173. doi:10.1111/j.1464-5491.2006.01943.x
236. Barnard KD, Skinner TC, Peveler R. (2006) The prevalence of co-morbid depression in adults with type 1 diabetes: systematic literature review. Diabet Med 23(4):445-448. doi:10.1111/j.1464-5491.2006.01814.x
237. Martinowich K, Lu B. (2008) Interaction between BDNF and serotonin: role in mood disorders. Neuropsychopharmacology 33(1):73-83. doi:10.1038/sj.npp. 1301571
238. Broderick PA, Jacoby J.H. (1989) Central monoamine dysfunction in diabetes: psychotherapeutic implications: electro-analysis by voltammetry. Acta Physiol Pharmacol Latinoam 39(3):211-225
239. Chen CC, Yang J.C. (1991) Effects of short and long-lasting diabetes mellitus on mouse brain monoamines. Brain Res 552 (1):175-179
240. Lackovic Z, Salkovic M, Kuci Z., Relja M. (1990) Effect of long-lasting diabetes mellitus on rat and human brain monoamines. J Neurochem 54(1):143-147
241. Chu PC, Lin MT, Shian L.R., Leu S.Y. (1986) Alterations in physiologic functions and in brain monoamine content in streptozocin-diabetic rats. Diabetes 35(4):481-485
242. Trulson ME, Jacoby JH, MacKenzie R.G. (1986) Streptozotocin-induced diabetes reduces brain serotonin synthesis in rats. J Neurochem 46(4):1068-1072
243. Crandall EA, Gillis MA, Fernstrom J.D. (1981) Reduction in brain serotonin synthesis rate in streptozotocin-diabetic rats. Endocrinology 109(1):310-312
244. Sandrini M, Vitale G, Vergoni A.V., Ottani A., Bertolini A. (1997) Streptozotocin-induced diabetes provokes changes in serotonin concentration and on 5-HT1A and 5-HT2 receptors in the rat brain. Life Sci 60(16):1393-1397
245. Sumiyoshi T, Ichikawa J, Meltzer H.Y. (1997) The effect of streptozotocin-induced diabetes on dopamine2, serotonin1A and serotonin2A receptors in the rat brain. Neuropsychopharmacology 16(3):183-190. doi:10.1016/S0893-133X(96)00185-6
246. Li JX, France C.P. (2008) Food restriction and streptozotocin treatment decrease 5-HT1A and 5-HT2A receptor-mediated behavioral effects in rats. Behav Pharmacol 19(4):292-297. doi:10.1097/FBP.0b013e328308f1d6
247. 3H] MDL100907 binding to 5HT2A receptors in cerebral cortex and brain stem of streptozotocin induced diabetic rats. Mol Cell Biochem 199 (1-2):81-85
248. Price JC, Kelley DE, Ryan C.M., Meltzer CC, Drevets WC, Mathis CA, Mazumdar S, Reynolds CF 3rd (2002) Evidence of increased serotonin-1A receptor binding in type 2 diabetes: a positron emission tomography study. Brain Res 927(1):97-103
249. Bellush LL, Reid SG, North D. (1991) The functional significance of biochemical alterations in streptozotocin-induced diabetes. Physiol Behav 50(5):973-981
250. DellaGioia N, Hannestad J. (2010) A critical review of human endotoxin administration as an experimental paradigm of depression. Neurosci Biobehav Rev 34(1):130-143. doi:10.1016/j.neubiorev.2009.07.014
251. Dunn AJ, Swiergiel AH, de Beaurepaire R (2005) Cytokines as mediators of depression: what can we learn from animal studies? Neurosci Biobehav Rev 29(4-5):891-909. doi:10.1016/j.neubiorev.2005.03.023
252. Raedler TJ (2011) Inflammatory mechanisms in major depressive disorder. Curr Opin psychiatry 24(6):519-525. doi:10.1097/YCO.0b013e32834b9db6
253. Maes M, Song C, Yirmiya R. (2012) Targeting IL-1 in depression. Expert Opin Ther targets. doi:10.1517/14728222.2012.718331
254. Song C, Manku MS, Horrobin D.F. (2008) Long-chain polyunsat-urated fatty acids modulate interleukin-1beta-induced changes in behavior, monoaminergic neurotransmitters, and brain inflammation in rats. J Nutr 138(5):954-963
255. Yin DM, Chen YJ, Sathyamurthy A, Xiong W.C., Mei L. (2012) Synaptic dysfunction in schizophrenia. Adv Exp Med Biol 970:493-516. doi:10.1007/978-3- 7091-0932-8-22
256. Muller N, Myint AM, Schwarz M.J. (2012) Inflammation in schizophrenia. Adv Protein Chem Struct Biol 88:49-68. doi:10.1016/b978-0-12-398314-5.00003-9
257. Leonard BE, Schwarz M, Myint A.M. (2012) The metabolic syndrome in schizophrenia: is inflammation a contributing cause? J Psychopharmacol (Oxford, England) 26(5 Suppl):33-41. doi:10.1177/0269881111431622
258. Guest PC, Schwarz E, Krishnamurthy D., Harris LW, Leweke FM, Rothermundt M, van Beveren NJ, Spain M, Barnes A, Steiner J, Rahmoune H, Bahn S (2011) Altered levels of circulating insulin and other neuroendocrine hormones associated with the onset of schizophrenia. Psychoneuroendocrinology 36(7):1092-1096. doi:10.1016/j.psyneuen.2010.12.018
259. Venkatasubramanian G, Chittiprol S, Neelakantachar N., Naveen MN, Thirthall J, Gangadhar BN, Shetty K.T. (2007) Insulin and insulin-like growth factor-1 abnormalities in antipsychotic-naive schizophrenia. Am J Psychiatry 164(10):1557-1560. doi:10.1176/appi.2007.07020233
260. Cohn TA, Remington G, Zipursky R.B., Azad A., Connolly P, Wolever T.M. (2006) Insulin resistance and adiponectin levels in drug-free patients with schizophrenia: a preliminary report. Can J Psychiatry 51(6):382-386
261. van Nimwegen L.J., Storosum JG, Blumer R.M., Allick G., Venema HW, de Haan L, Becker H, van Amelsvoort T, Ackermans MT, Fliers E, Serlie MJ, Sauerwein HP (2008) Hepatic insulin resistance in antipsychotic naive schizophrenic patients: stable isotope studies of glucose metabolism. J Clin Endocrinol Metab 93(2):572-577. doi:10.1210/jc.2007-1167
262. Kirkpatrick B, Miller BJ, Garcia-Rizo C, Fernandez-Egea E, Bernardo M. (2010) Is abnormal glucose tolerance in antipsychotic-naive patients with nonaffective psychosis confounded by poor health habits? Schizophr Bull. doi:10.1093/schbul/sbq058
263. Zhao Z, Ksiezak-Reding H, Riggio S., Haroutunian V, Pasinetti G.M. (2006) Insulin receptor deficits in schizophrenia and in cellular and animal models of insulin receptor dysfunction. Schizophr Res 84(1):1-14. doi:10.1016/j.schres. 2006.02.009
264. Guest PC, Wang L, Harris L.W., Burling K., Levin Y, Ernst A, Wayland M.T., Umrania Y., Herberth M, Koethe D, van Beveren JM, Rothermundt M, McAllister G, Leweke FM, Steiner J, Bahn S (2010) Increased levels of circulating insulin-related peptides in first-onset, antipsychotic naive schizophrenia patients. Mol Psychiatry 15(2):118-119. doi:10.1038/mp.2009.81
265. Spelman LM, Walsh PI, Sharifi N, Collins P., Thakore J.H. (2007) Impaired glucose tolerance in first-episode drug-naive patients with schizophrenia. Diabet Med 24(5):481-485. doi:10.1111/j.1464-5491.2007.02092.x
266. Ryan MC, Collins P, Thakore J.H. (2003) Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 160(2):284-289
267. Maric N, Doknic M, Damjanovic A., Pekic S, Jasovic-Gasic M, Popovic V. (2008) Glucoregulation in normal weight schizophrenia patients treated by first generation antipsychotics. Srp Arh Celok Lek 136 (3-4):110-115
268. Oresic M, Seppanen-Laakso T, Sun D., Tang J, Therman S, Viehman R., Mustonen U, van Erp TG, Hyotylainen T, Thompson P, Toga AW, Huttunen MO, Suvisaari J, Kaprio J, Lonnqvist J, Cannon TD (2012) Phospholipids and insulin resistance in psychosis: a lipidomics study of twin pairs discordant for schizophrenia. Genome Med 4(1):1. doi:10.1186/gm300
269. Dasgupta A, Singh OP, Rout J.K., Saha T., Mandal S. (2010) Insulin resistance and metabolic profile in antipsychotic naive schizophrenia patients. Prog Neuropsychopharmacol Biol Psychiatry 34(7):1202-1207. doi:10.1016/j.pnpbp. 2010.06.011
270. Altar CA, Hunt RA, Jurata L.W., Webster MJ, Derby E, Gallagher P, Lemire A., Brockman J, Laeng P (2008) Insulin, IGF-1, and muscarinic agonists modulate schizophrenia-associated genes in human neuroblastoma cells. Biol Psychiatry 64(12):1077-1087. doi:10.1016/j.biopsych.2008.08.031
271. Fan X, Copeland PM, Liu E.Y., Chiang E., Freudenreich O, Goff DC, Henderson D.C. (2011) No effect of single-dose intranasal insulin treatment on verbal memory and sustained attention in patients with schizophrenia. J Clin Psychopharmacol 31(2):231-234. doi:10.1097/JCP.0b013e31820ebd0e
272. Lozovsky D, Saller CF, Kopin I.J. (1981) Dopamine receptor binding is increased in diabetic rats. Science 214(4524):1031-1033
273. Jones K (2000) Insulin coma therapy in schizophrenia. J R Soc Med 93(3):147-149